Gprc5a deletion enhances the transformed phenotype in normal and malignant lung epithelial cells by eliciting persistent Stat3 signaling induced by autocrine leukemia inhibitory factor

Cancer Research

Volumn 70, Issue 21, 2010, Pages 8917-8926

  Chen, Yulong ^a   Deng, Jiong ^a   Fujimoto, Junya ^a   Kadara, Humam ^a   Men, Taoyan ^a   Lotan, Dafna ^a   Lotan, Reuben ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR KINASE 5; GROWTH FACTOR; JANUS KINASE 2 INHIBITOR; LEUKEMIA INHIBITORY FACTOR; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; STAT3 PROTEIN; TYROSINE;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CANCER CELL; CELL ISOLATION; CELL SURVIVAL; CELL TYPE; CULTURE MEDIUM; IN VITRO STUDY; LUNG ADENOCARCINOMA; LUNG ALVEOLUS EPITHELIUM; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; KIDNEY; LEUKEMIA INHIBITORY FACTOR; LUNG; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHENOTYPE; RECEPTORS, G-PROTEIN-COUPLED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEQUENCE DELETION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 78449304323     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0518     Document Type: Article

References (37)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Meuwissen R, Berns A. Mouse models for human lung cancer. Genes Dev 2005;19:643-64.
3. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2004;4:97-105.
4. Bromberg JF, Wrzeszczynska MH, Devgan G, et al. Stat3 as an oncogene. Cell 1999;98:295-303.
5. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009;9:798-809.
6. Yeh TC, Pellegrini S. The Janus kinase family of protein tyrosine kinases and their role in signaling. Cell Mol Life Sci 1999;55:1523-34.
7. Reich NC, Liu L. Tracking STAT nuclear traffic. Nat Rev Immunol 2006;6:602-12.
8. Grivennikov S, Karin E, Terzic J, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009;15:103-13.
9. Bollrath J, Phesse TJ, von Burstin VA, et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009;15:91-102.
10. Sekkai D, Gruel G, Herry M, et al. Microarray analysis of LIF/Stat3 transcriptional targets in embryonic stem cells. Stem Cells 2005;23:1634-42.
11. Costantino L, Barlocco D. STAT 3 as a target for cancer drug discovery. Curr Med Chem 2008;15:834-43.
12. Meydan N, Grunberger T, Dadi H, et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 1996;379:645-8.
13. Levitzki A. Tyrosine kinases as targets for cancer therapy. Eur J Cancer 2002;38 Suppl 5:S11-8.
14. Cheng Y, Lotan R. Molecular cloning and characterization of a novel retinoic acid-inducible gene that encodes a putative G protein-coupled receptor. J Biol Chem 1998;273:35008-15.
15. Tao Q, Fujimoto J, Men T, et al. Identification of the retinoic acid-inducible Gprc5a as a new lung tumor suppressor gene. J Natl Cancer Inst 2007;99:1668-82.
16. Burger M, Hartmann T, Burger JA, Schraufstatter I. KSHV-GPCR and CXCR2 transforming capacity and angiogenic responses are mediated through a JAK2-3-dependent pathway. Oncogene 2005;24:2067-75.
17. Ho MK, Su Y, Yeung WW, Wong YH. Regulation of transcription factors by heterotrimeric G proteins. Curr Mol Pharmacol 2009;2:19-31.
18. Bromberg JF, Horvath CM, Besser D, Lathem WW, Darnell JE, Jr. Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol 1998;18:2553-8.
19. Wen Z, Darnell JE, Jr. Mapping of Stat3 serine phosphorylation to a single residue (727) and evidence that serine phosphorylation has no influence on DNA binding of Stat1 and Stat3. Nucleic Acids Res 1997;25:2062-7.
20. Tucker RW, Sanford KK, Handleman SL, Jones GM. Colony morphology and growth in agarose as tests for spontaneous neoplastic transformation in vitro. Cancer Res 1977;37:1571-9.
21. Song L, Turkson J, Karras JG, Jove R, Haura EB. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene 2003;22:4150-65.
22. Gao J, McConnell MJ, Yu B, et al. MUC1 is a downstream target of STAT3 and regulates lung cancer cell survival and invasion. Int J Oncol 2009;35:337-45.
23. Gao SP, Mark KG, Leslie K, et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 2007;117:3846-56.
24. Alvarez JV, Greulich H, Sellers WR, Meyerson M, Frank DA. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res 2006;66:3162-8.
25. Politi K, Zakowski MF, Fan PD, Schonfeld EA, Pao W, Varmus HE. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 2006;20:1496-510.
26. Lee H, Herrmann A, Deng JH, et al. Persistently activated Stat3 maintains constitutive NF-κB activity in tumors. Cancer Cell 2009;15:283-93.
27. Nakajima K, Yamanaka Y, Nakae K, et al. A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J 1996;15:3651-8.
28. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
29. Sato M, Vaughan MB, Girard L, et al. Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res 2006;66:2116-28.
30. Li Y, Du H, Qin Y, Roberts J, Cummings OW, Yan C. Activation of the signal transducers and activators of the transcription 3 pathway in alveolar epithelial cells induces inflammation and adenocarcinomas in mouse lung. Cancer Res 2007;67:8494-503.
31. Kamohara H, Sakamoto K, Ishiko T, et al. Human carcinoma cell lines produce biologically active leukemia inhibitory factor (LIF). Res Commun Mol Pathol Pharmacol 1994;85:131-40.
32. Kellokumpu-Lehtinen P, Talpaz M, Harris D, Van Q, Kurzrock R, Estrov Z. Leukemia-inhibitory factor stimulates breast, kidney and prostate cancer cell proliferation by paracrine and autocrine pathways. Int J Cancer 1996;66:515-9.
33. He B, You L, Uematsu K, et al. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci U S A 2003;100:14133-8.
34. Hedvat M, Huszar D, Herrmann A, et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 2009;16:487-97.
35. Qu P, Roberts J, Li Y, et al. Stat3 downstream genes serve as biomarkers in human lung carcinomas and chronic obstructive pulmonary disease. Lung Cancer 2009;63:341-7.
36. Hokuto I, Ikegami M, Yoshida M, et al. Stat-3 is required for pulmonary homeostasis during hyperoxia. J Clin Invest 2004;113:28-37. (Pubitemid 38541629)
37. Escary JL, Perreau J, Duménil D, Ezine S, Brûlet P. Leukaemia inhibitory factor is necessary for maintenance of haematopoietic stem cells and thymocyte stimulation. Nature 1993;363:361-4.